The addition of hyperthermia (HT) to regional isolated perfusion (RIP) with Melphalan theoretically has two advantages. Firstly, heat can selectively kill cells in poorly vascularised areas that are usually not reached by the drug. Secondly, in vitro data have revealed that the effect of Melphalan is enhanced at temperatures 39-45°C. However, for the simultaneous application of Melphalan and HT, as it is given in most institutes, both normal and tumour tissues within the volume are treated with both modalities. It is unclear whether-for the same heat dose-the cytoxicity of Melphalan is enhanced more in tumour tissue than in normal tissues. As the applied dose of Melphalan in RIP is selected on maximum acceptable toxicity, any enhancement of toxicity is undesired. Indeed, Melphalan application at temperatures >41"C has resulted in unacceptable toxicity. In most institutes, the hyperthermia dose is reduced in comparison to application as a single-modality treatment, to allow simultaneous combination without unacceptable toxicity. In this review, the rationale for two different approaches is summarised which may make it possible to improve the benefit from the theoretical advantage of the use of HT in RIP. It is meant to stimulate discussion as a possible first step in the design of new treatment protocols. 0 1997 Elsevier Science Ltd.
INTRODUCTION

REGIONAL ISOLATED
perfusion (RIP) with Melphalan and hyperthermia (HT) is a generally accepted treatment for locally or regionally advanced melanoma of an extremity. However, the role of HT in RIP with Melphalan, and the optimum schedule for combining the two modalities, are not well defined. Reports of better results from current HT perfusions in comparison with those from earlier studies may have to be explained by the fact that in those early days no special measures were taken to prevent the limb from cooling down during preparative surgery. Tissue temperatures of the limb were probably as low as 30°C [l] .
exposure of tumour cells to chemotherapy. This background is the reason that the members of the 'AmRo perfusion team', a co-operative group from both the Dr Daniel den Hoed Cancer Center in Rotterdam and The Netherlands Cancer Institute in Amsterdam, have chosen to apply RIP with Melphalan at controlled normothermic (37-38°C) temperatures [2] .
However, HT is an interesting modality in the treatment of cancer. Recently, the therapeutic gain by HT in addition to radiotherapy, was proven by randomised comparative studies for various types of tumour [3-61. Both experimental and clinical data indicate that the application of HT results in tumour cell kill at dose levels which are not toxic to normal tissues. HT is especially toxic to cells in insufficiently perfused areas of tumours, which are hypoxic and acidic [7, 81. HT has a greater effect on tumour tissue than on normal tissue due to the indirect effects of inducing vascular stasis. Such vascular stasis is caused by heat damage the thermal enhancement ratio (TER, defined as the ratio of the drug dose required to produce a certain biological effect and the drug dose which in combination with HT leads to the same effect) for tumour growth delay varied from 2 to 4.3 [ 121. For bone marrow toxicity, the TER varied from 1.7 to 2.9. In a study in dogs with spontaneous malignant melanoma, whole body HT of 60 min at 41.9-42°C enhanced the probability of severe haematological toxicity from Melphalan with a factor of 1.9, whereas no improvement in tumour response was found in the combined treated group [13] . These results emphasise that normal tissue toxicity is exacerbated by simultaneous application of Melphalan and HT. Since the relatively mild HT temperature do not induce such effects in normal tissue when applied as a single treatment (see below), it must be concluded that these are the result of thermal enhancement of drug toxicity. A therapeutic gain is not achieved as a rule by the simultaneous combination of whole body HT and systemic application of Melphalan.
Similar types of problems may also be encountered when using RIP, but this has not been tested in animals.
Clinical data
Clinical [ 191. A complete response was achieved in 9 patients, whilst 1 patient showed a partial response. Impressive tumour regressions and central tumour necrosis were found in most of the patients within 1 week following HT perfusion; one example is given in Figure 1 . The median duration of complete response was 5+ (3+-12+) months.
Two patients developed a recurrence in the perfused region, both after 5 months. The schedule was well tolerated with few side-effects.
It can be deduced from these initial data that the extra perfusion with heat alone may lead to better tumour control than normothermic or 'mild' HT RIP with Melphalan (see Table 1 ). However, the major disadvantage of the sequential combination is that it requires two surgical procedures. MORE HEAT, LESS DRUG: AN' ALTERNATIVE APPROACH Another approach, in which both the disadvantage of the two surgical procedures can be avoided and the advantage of optimum use of the two treatment modalities may be exploited, would be to administer HT at the maximum tolerated level, and reduce the simultaneously administered Melphalan dose on the basis of the maximum acceptable toxicity at that temperature.
The only assumption made for this approach is that, for the same heat dose, the cytoxicity of Melphalan is equally enhanced in well-perfused tumour tissue compared to normal tissues. With this assumption, the biological rationale for the 'more heat-less drug approach' is as follows.
1. The normal tissue toxicity remains within acceptable levels, since the Melphalan dose is reduced according to the enhancement obtained by the simultaneous heat treatment.
Such a new tolerance dose should be derived from phase I studies. Yet, it already has been suggested that the Melphalan dose to be given is 12 mg/l perfused tissue when tissue temperatures are increased to 41.5' C or higher, whereas it can be 14 mgil perfused tissue at a temperature of 39' C [ 181.
2. As a consequence of our assumption, the antitumour efficacy of this approach in well-perfused tumour tissues is similar to that achieved with 'standard' application. 3. The main beneficial effect of this approach concerns the cells in insufficiently perfused parts of the tumour. In view of the experience with HT alone in the sequentially applied combination, an HT dose of 2 h at approximately 42.5'C is highly effective. Putative negative effects of HT-induced stasis [9] on drug penetrance, if occurring at all during treatment, are likely to be compensated for by the preferential heat kill of cells in these areas of vascular occlusion and by the drug sensitisation effect.
As both drug and heat cytotoxicity are used at 'full' capacity, that is, to the limits of tolerance, in theory this approach can be expected to give similar good responses compared to the sequential combination of HT and Melphalan. scheduling or adaptations in drug dose lead to unacceptable toxicity due to heat and drug interaction. Yet, true HT is tolerable and may lead to better tumour control if applied separately from Melphalan. When the two treatment modalities are combined sequentially, both HT and Melphalan can be administered at optimum levels. True HT perfusion will kill cells in the hypoxic parts of the tumour, without causing normal tissue toxicity. The second normothermic perfusion with Melphalan will attack the residual well-perfused parts of the tumour. However, the need for two surgical procedures is a major disadvantage. As an alternative approach, it is suggested that a maximally tolerated HT treatment is applied simultaneously with a reduced dose of Melphalan. With the appropriate dose reduction (based on the enhancement factor for drug toxicity), this (a) should not compromise the effect of the drug in well-perfused tumour areas; (b) should not lead to an unacceptable toxicity in normal tissues; (c) maximally utilises the selective effect of HT in poorly perfused areas of the tumour; and (d) require only one surgical procedure. Such an approach deserves further attention.
CONCLUSION
